Aktis Oncology, Inc. (AKTS)
18.14
+0.40
(+2.23%)
USD |
NASDAQ |
Oct 09, 16:00
18.14
0.00 (0.00%)
After-Hours: 20:00
Aktis Oncology Enterprise Value : 475.28M for Oct. 8, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 08, 2026 | 475.28M |
| October 07, 2026 | 489.66M |
| October 06, 2026 | 481.92M |
| October 05, 2026 | 518.43M |
| October 02, 2026 | 518.43M |
| October 01, 2026 | 518.43M |
| September 30, 2026 | 570.98M |
| September 29, 2026 | 583.15M |
| September 28, 2026 | 564.34M |
| September 25, 2026 | 568.77M |
| September 24, 2026 | 579.83M |
| September 23, 2026 | 584.81M |
| September 22, 2026 | 717.03M |
| September 21, 2026 | 679.41M |
| September 18, 2026 | 704.30M |
| September 17, 2026 | 758.51M |
| September 16, 2026 | 750.22M |
| September 15, 2026 | 733.62M |
| September 14, 2026 | 775.66M |
| September 11, 2026 | 782.86M |
| September 10, 2026 | 818.26M |
| September 09, 2026 | 824.90M |
| September 08, 2026 | 878.00M |
| September 04, 2026 | 990.30M |
| September 03, 2026 | 968.17M |
| Date | Value |
|---|---|
| September 02, 2026 | 983.11M |
| September 01, 2026 | 931.66M |
| August 31, 2026 | 927.24M |
| August 28, 2026 | 920.05M |
| August 27, 2026 | 942.17M |
| August 26, 2026 | 960.43M |
| August 25, 2026 | 970.39M |
| August 24, 2026 | 931.11M |
| August 21, 2026 | 825.45M |
| August 20, 2026 | 821.58M |
| August 19, 2026 | 878.00M |
| August 18, 2026 | 876.90M |
| August 17, 2026 | 861.41M |
| August 14, 2026 | 873.03M |
| August 13, 2026 | 809.96M |
| August 12, 2026 | 821.58M |
| August 11, 2026 | 864.17M |
| August 10, 2026 | 827.11M |
| August 07, 2026 | 828.77M |
| August 06, 2026 | 790.60M |
| August 05, 2026 | 746.90M |
| August 04, 2026 | 757.41M |
| August 03, 2026 | 723.66M |
| July 31, 2026 | 714.81M |
| July 30, 2026 | 766.26M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.488B |
| Alnylam Pharmaceuticals, Inc. | 29.71B |
| Anika Therapeutics, Inc. | 244.19M |
| Savara, Inc. | 849.45M |
| Vericel Corp. | 1.982B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -24.14M |
| Revenue (Quarterly) | 3.384M |
| Total Expenses (Quarterly) | 27.53M |
| EPS Diluted (Quarterly) | -0.4364 |
| Gross Profit Margin (Quarterly) | 74.02% |
| Profit Margin (Quarterly) | -713.5% |
| Earnings Yield | -7.60% |
| Normalized Earnings Yield | -7.600 |